Please enable Javascript
Zachary Bessette
Zachary Bessette
Articles by Zachary Bessette
Early Discontinuation of Upfront ARSIs Without Disease Progression in Patients With mCSPC
Zachary Bessette
mCSPC
|
April 27, 2025
A recent study evaluated the impact of early withdrawal of upfront ARSIs on clinical outcomes in patients with mCSPC.
Read More
Impact of Cytoreductive Nephrectomy, Timing of Systemic Therapy in Metastatic nccRCC
Zachary Bessette
nccRCC
|
April 27, 2025
CN may improve OS for patients with metastatic nccRCC compared with systemic therapy alone, especially when combined with IO.
Read More
Comparing ctDNA, Conventional Imaging for Monitoring Patients With Localized RCC After Surgery
Zachary Bessette
Localized Renal Cell Carcinoma
|
April 27, 2025
A research analysis evaluated tumor-informed ctDNA analysis versus traditional imaging techniques for localized RCC.
Read More
PROs From Patients With Localized Prostate Cancer Receiving HIFU: 3-Year Update
Zachary Bessette
Localized
|
April 26, 2025
Research sheds light on the patient-reported outcomes from a 3-year focal therapy program for localized PCa using HIFU.
Read More
Light-Activated TLD-1433 for BCG-Unresponsive NMIBC Carcinoma In Situ
Zachary Bessette
Urothelial Carcinoma
|
April 27, 2025
Interim data may support the use of light-activated TLD-1433 photodynamic therapy for patients with BCG–unresponsive NMIBC.
Read More
Neoadjuvant Mitomycin C for NMIBC: A Phase 3 Study
Zachary Bessette
Urothelial Carcinoma
|
April 27, 2025
Dr. Roberto Contieri presented on the safety, tolerability, and efficacy of neoadjuvant mitomycin C in patients with NMIBC.
Read More
TALAPRO-2: Final OS After First-Line Treatment for Patients With mCRPC
Zachary Bessette
CRPC
|
February 13, 2025
Tala/enza demonstrated improvement in OS compared with enza alone as 1L treatment in patients with mCRPC.
Read More
CheckMate 214: Evaluating KIM-1 as a Biomarker in Advanced RCC
Zachary Bessette
Renal Cell Carcinoma
|
February 18, 2025
Increased levels of circulating KIM-1 are associated with worse outcomes for patients receiving nivo/ipi or sunitinib alone.
Read More
FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection
Zachary Bessette
Renal Cell Carcinoma
|
January 2, 2025
The FDA has approved nivo for subcutaneous injection for all solid tumors for which nivo is indicated as a monotherapy.
Read More
CONTACT-02: Final OS Results of Cabo/Atezo Versus Second Novel Hormonal Therapy for mCRPC
Zachary Bessette
CRPC
|
October 1, 2024
The final results of the CONTACT-02 trial show favorable, but not statistically significant, benefit for cabo/atezo in mCRPC.
Read More
NIAGARA Offers Paradigm-Shift for Neoadjuvant Treatment of MIBC
Zachary Bessette
Muscle Invasive Urothelial Carcinoma
|
September 17, 2024
Perioperative durvalumab with NAC offers “meaningful improvement” in EFS and OS for patients with cisplatin-ineligible ...
Read More
SunRISe-1: TAR-200, Cetrelimab for BCG-Unresponsive High-Risk NMIBC
Zachary Bessette
Non-Muscle Invasive Urothelial Carcinoma
|
September 17, 2024
Results of SunRISe-1 provide support for TAR-200 monotherapy in patients with BCG-unresponsive high-risk NMIBC.
Read More
EV-302: Nectin-4 Expression and Response to First-Line EV/Pembro
Zachary Bessette
Advanced Urothelial Carcinoma
|
September 13, 2024
EV/pembro may offer first-line PFS and OS benefit in patients with la/mUC, regardless of Nectin-4 expression.
Read More
Futibatinib Plus Pembrolizumab for Patients With Metastatic Urothelial Carcinoma
Zachary Bessette
Advanced Urothelial Carcinoma
|
September 12, 2024
A phase 2 study highlights the “encouraging” antitumor activity from futibatinib plus pembrolizumab for patients with ...
Read More
Nivo, Chemoradiotherapy for Patients With nmMIBC Not Undergoing Cystectomy
Zachary Bessette
Muscle Invasive Urothelial Carcinoma
|
September 11, 2024
The addition of nivo to trimodality therapy may improve RFS in patients with non-metastatic muscle-invasive bladder cancer.
Read More
FDA Accepts New Drug Application for Prostate Cancer Imaging Agent
Zachary Bessette
Prostate Cancer Diagnostics
|
July 24, 2024
The FDA has accepted an NDA for TLX007-CDx, a cold kit for the preparation of PSMA-PET imaging for prostate cancer.
Read More
PSMA Tandem Treatment Offers Benefit for Patients With mCRPC
Zachary Bessette
RLT
|
June 11, 2024
A phase 3 trial offers the first randomized evidence of the benefit of PSMA tandem therapy in patients with mCRPC.
Read More
18F-rhPSMA-7 Versus Conventional Salvage Radiotherapy for BCR
Zachary Bessette
Prostate Cancer Diagnostics
|
June 11, 2024
New research provides evidence of 18F-rhPSMA-7 leading to more favorable disease outcomes for patients with BCR after RP.
Read More
NEPTUNES: Nivolumab, Ipilimumab for Metastatic Prostate Cancer With an Immunogenic Signature
Zachary Bessette
CRPC
|
June 4, 2024
Dr. Mark David Linch presented the results of NEPTUNES: a multicenter, 2-cohot, biomarker-selected, phase 2 trial.
Read More
CHAARTED2: Cabazitaxel Plus Abiraterone After Initial Docetaxel for mCRPC
Zachary Bessette
CRPC
|
June 3, 2024
Results from the CHAARTED2 trial was presented by Dr. Kyriakopoulos of the University of Wisconsin Carbone Cancer Center.
Read More
Load More